NCT02350478View on ClinicalTrials.gov

Effects of Linagliptin on Endothelial Function

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

March 31, 2017

Conditions
Type 2 DiabetesCoronary Artery Disease
Interventions
DRUG

Linagliptin

The subject will receive Linagliptin 5mg orally once daily for 12 weeks.

DRUG

Placebo

The subject will receive placebo orally once daily for 12 weeks.

Trial Locations (1)

8036

Medical University of Graz, Department for Internal Medicine, Graz

All Listed Sponsors
lead

Medical University of Graz

OTHER

NCT02350478 - Effects of Linagliptin on Endothelial Function | Biotech Hunter | Biotech Hunter